BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Minghui Pharma's MH004 Cream Succeeds in Phase 2 Trial for Atopic Dermatitis, Global Phase 3 MRCT Cleared by FDA

Study met both primary and all key secondary endpoints Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score was -78.7% in...

April 14, 2023 | News

Zenshine's ZX-7101A meets primary endpoint in Phase 2 flu treatment study

Interim analysis of the phase 2 cohort of ZX-7101A phase 2/3 adaptive design pivotal study (registration number: CTR20221729), a multicenter, randomized, d...

April 14, 2023 | News

CPHI Japan: the rise of Chinese innovation the big macro story for APAC in 2023

“Historically, we have seen a dual strategy of focusing on China and the US for emerging innovators in China. However, a series of recent setbacks wi...

April 13, 2023 | News

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

Currently, commercially available cell therapies, such as CD19 CAR-T, are designed for the treatment of B cell lymphoma or acute lymphoblastic leukemia. Tr...

April 12, 2023 | News

Boan Biotech's Biologics License Application for Boyounuo® (Bevacizumab Injection) Accepted in Brazil

Envisioned to be "a leading global biopharmaceutical company", Boan Biotech develops biologics for both Chinese and international markets, including E...

April 12, 2023 | News

JW Therapeutics' Relma-cel approved for systemic lupus erythematosus trial.

SLE is a complex autoimmune disease with diverse clinical manifestations involving many organs and systems. It is estimated that China has 1 mill...

April 11, 2023 | News

Asieris subsidiary obtains "Drug Distribution License" for commercialization strategy.

Hainan Asieris' acquisition of the Drug Distribution Licence is a critical step towards improvement in the quality of drug circulation services, standardiz...

April 11, 2023 | News

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

The investigational new drug (IND) application was submitted by Telix's partner in the Greater China region, Grand Pharmaceutical Group Limited (...

April 11, 2023 | News

Evopoint, MSD Partner for Clinical Trial of XNW5004 with KEYTRUDA in Solid Tumors.

XNW5004 is a rationally designed, highly selective and potent EZH2 inhibitor with potentially best-in-class efficacy and safety profile demonstrated in a P...

April 10, 2023 | News

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

Developed with site specific conjugate technology, 9MW2821 is China's first, global second Nectin-4 targeted ADC approved for clinical study. The...

April 08, 2023 | News

First patient dosed in China Phase III trial for COPD, announces Nuance Pharma

Ensifentrine is a first-in-class, selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") combining bronchodilator and non-s...

April 07, 2023 | News

Singapore HSA Accepts Everest Medicines' Nefecon Application for IgA Nephropathy Treatment

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commerc...

April 06, 2023 | News

WuXi STA Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System

WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announces that it has added two 2,000 L reactors and a lar...

April 06, 2023 | News

Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis

"BSI-045B is a next generation anti-TSLP mAb with high affinity and bioactivity that has the potential to offer greater therapeutic potential for patients ...

April 05, 2023 | News

Stay Connected